Ikarian Capital’s SELLAS Life Sciences SLS Stock Holding History

Ikarian Capital’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.24M	Buy	+354,700	New	+$2.45M	0.56%	56

Other funds holding SLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Ikarian Capital's SLS Position: Q2 2021 in Review

Ikarian Capital sold out of SELLAS Life Sciences (SLS) in Q2 2021, closing a stake of 48,053 shares — an estimated $410K sold.

Ikarian Capital first reported a position in SLS in Q1 2021 and held it in 1 quarter. The position peaked at $410K in Q1 2021. 29 funds tracked by Wall St. Rank hold SLS as of Q2 2021.

Ikarian Capital reported no remaining SELLAS Life Sciences position as of Q2 2021 after selling out during the quarter.
Ikarian Capital sold 48,053 SELLAS Life Sciences shares in Q2 2021, an estimated $410K.
Ikarian Capital first reported a position in SELLAS Life Sciences in Q1 2021 and held it in 1 quarter.
Ikarian Capital's SELLAS Life Sciences position peaked at $410K in Q1 2021.
29 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2021.

Based on Ikarian Capital's 13F filing for Q2 2021, filed 16 Aug 2021.